This query gets searched a lot, but most answers online are just vibes. Here’s my attempt to separate what has human data from what doesn’t. Correct me if I’m wrong anywhere. The big problem: women are underrepresented Most early peptide research is in male rodents or mostly male cohorts. Hormonal cycles, perimenopause, pregnancy, and breastfeeding all change the picture, so “it worked in a study” doesn’t always carry over. Compounds with human trial data - Semaglutide / tirzepatide: The big obesity trials enrolled mostly women, and subgroup analyses generally show women losing as much or more than men on average. Both are approved drugs, so the prescribing info is public. - Bremelanotide (PT-141): FDA approved for HSDD in premenopausal women, one of the few peptides with women-specific approval data. - Oral collagen peptides: Some trials show benefits for skin hydration and elasticity. Quality varies, and many studies are industry funded. Interesting but early - GHK-Cu: Lots of interest for skin and wound healing, but mostly small studies or topical work. - GH secretagogues (ipamorelin, CJC-1295, etc.): The mechanism is interesting, but women-specific human data is thin. - Kisspeptin, oxytocin: Active research areas, nowhere near “stack” territory. Before anyone calls something a “stack” - There is basically no peer-reviewed data on combining these compounds, in women or anyone else. - Tirzepatide labeling flags reduced effectiveness of oral contraceptives, and semaglutide labeling advises stopping well before a planned pregnancy. Hormonal status matters a lot. - Nothing here replaces a clinician who knows your history. Sourcing Quality control is the biggest variable in this space. Kylo Peptides is one of the many suppliers of research compounds out there, so compare a few for yourself. Check batch-level third-party testing and COAs whoever you pick, and don’t rely on any brand’s marketing. Education and research discussion only. Not medical advice.